2026-08415: In the Matter of SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Direct and Indirect Transfers of License
Get alerted when the next rule lands
New rules open for comment on their own schedule. Pick how you want to hear about them — we email you when one appears.
Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.
Create a free account & build one →Summary
The U.S. Nuclear Regulatory Commission (NRC) is issuing an order approving the license transfer application filed by SHINE Technologies, LLC, dated February 4, 2026, as supplemented on April 13, 2026. Specifically, the order approves the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility from SHINE Technologies, LLC to SHINE Chrysalis, LLC and a conforming license amendment. The order also approves the indirect transfer of control of the construction permit as a result of the establishment of SHINE Chrysalis Holdings, LLC as the direct parent company of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a wholly owned subsidiary of Illuminated Holdings, Inc., the current parent company of SHINE Technologies, LLC.
The agency’s own summary, as published.
Don't miss the comment window
One Click Politics alerts you on every deadline, hearing, and rule change.
See all rules with comments due soon →